Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data
Michaël Hardy,
Isabelle Michaux,
Sarah Lessire,
Jonathan Douxfils,
Jean-Michel Dogné,
Marion Bareille,
Geoffrey Horlait,
Pierre Bulpa,
Celine Chapelle,
Silvy Laporte,
Sophie Testa,
Hugues Jacqmin,
Thomas Lecompte,
Alain Dive,
François Mullier
Affiliations
Michaël Hardy
Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium; Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium
Isabelle Michaux
Université catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium
Sarah Lessire
Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium
Jonathan Douxfils
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium; Qualiblood s.a., Namur, Belgium
Jean-Michel Dogné
Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
Marion Bareille
Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium
Geoffrey Horlait
Université catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium
Pierre Bulpa
Université catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium
Celine Chapelle
Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, F-42055 Saint-Etienne, France; SAINBIOSE U1059, Université Jean Monnet, University Lyon, INSERM, F-CRIN INNOVTE Network, F-42023 Saint-Etienne, France
Silvy Laporte
Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, F-42055 Saint-Etienne, France; SAINBIOSE U1059, Université Jean Monnet, University Lyon, INSERM, F-CRIN INNOVTE Network, F-42023 Saint-Etienne, France
Sophie Testa
Haemostasis and Thrombosis Center, Cremona Hospital, Cremona, Italy
Hugues Jacqmin
Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium
Thomas Lecompte
Département de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland
Alain Dive
Université catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium
François Mullier
Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium; Corresponding author.
This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.